ClinicalTrials.gg
Active, not recruitingNCT05873686Updated Sep 30, 2026

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

A Phase 1 interventional study of NXP900 in Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer) and Renal Cancer, sponsored by Nuvectis Pharma, Inc.. Active, not recruiting at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Nuvectis Pharma, Inc. · Phase 1, Interventional, and Treatment

Updated Sep 30, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
842nd of 2,998
140 · median 56
Started
2023
with 163 others
Phase 1
927 of 3,371
134 open now
Primary completion
2027-03
later than 340 of 892 live
Registered
2,864th of 3,371
by date

Among the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 842nd largest by planned enrollment of the 2,998 interventional ones that give a count, is one of 164 that started in 2023, is one of 927 in phase 1, reaches primary completion later than 340 of the 892 other live ones, and was the 2,864th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

03

Conditions studied

  • Advanced Solid Tumor
  • NSCLC (Non-small Cell Lung Cancer)
  • Renal Cancer
  • Mesothelioma
  • Non-Small Cell Squamous Lung Cancer
  • Non-small Cell Lung Adenocarcinoma

Keywords

  • Solid Tumor
  • Carcinoma
  • Neoplasms
  • Adenocarcinoma
  • YES1
  • YAP1
  • TAZ1
  • NF2
  • FAT1
  • LATS1
  • TYMS
  • gene amplification
  • gene mutation
  • IDH1
  • IDH2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part A

Inclusion Criteria:

  1. Provide written .
  2. 18 years old or older.
  3. Advanced, , and/or progressive solid tumors for whom there is no authorized or effective therapy available, or for whom such therapies are considered inappropriate by the Investigator.
  4. according to (RECIST) Version 1.1.
  5. (ECOG) performance status of 0-1.

Exclusion Criteria:

  1. Subjects with known human epidermal growth factor receptor 2 (+) overexpressing .
  2. Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or agent within 28 days, (42 days for nitrosoureas, mitomycin-C) of first dose of NXP900. Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer.
  3. Ongoing toxic manifestations of previous treatments > Grade 2 with the exception of alopecia and neuropathy.
  4. Subjects with treated with evidence of progression within 28 days after central nervous system (CNS)-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the Screening period.
  5. Female subjects who can become pregnant (or are already pregnant or lactating), unless they have a negative serum pregnancy test before enrollment and agree to use at least one highly effective form of .
  6. Male subjects with partners of , unless they agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide).
  7. Major surgery from which the subject has not yet recovered.

Part B:

Inclusion Criteria:

  1. Provide written informed consent.
  2. 18 years old or older.
  3. Advanced, metastatic, and/or progressive solid tumors with pathogenic molecular alterations:

    1. Non-small cell lung cancer (adenocarcinoma); YES1, TYMS amplification or FAT1 pathogenic mutation
    2. Non-small cell lung cancer (squamous cell carcinoma); YES1, TYMS amplification or FAT1 pathogenic mutation
    3. Renal cancer; NF2 pathogenic mutation
    4. Mesothelioma; NF2 pathogenic mutation
    5. Other solid tumors with a NF2, FAT1 or LATS1 pathogenic gene mutation or TYMS, YAP1, YES1, or TAZ1 gene amplification, or cholangiocarcinoma with IDH1 or IDH2 mutations.
  4. Must have received 1-3 prior therapies appropriate for their tumor type and stage of disease
  5. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (or 1.1 for subjects with pleural mesothelioma).
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

Exclusion Criteria:

  1. Subjects with the following combination of cancer type and pathogenic molecular alterations are excluded:

    1. Subjects with colorectal cancer, glioma, melanoma, or anaplastic thyroid conditions with BRAF mutations.
    2. Subjects with NSCLC with BRAF or EGFR mutations or HER2 overexpression.
    3. Subjects with breast cancer, gastric cancer, esophageal junction adenocarcinoma or biliary cancer with HER2 alterations,
  2. Subjects with anal, penile, cervical or head and neck cancers with a prior history of human papilloma virus (HPV) infection.
  3. Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or investigational agent within 28 days (42 days for nitrosoureas, mitomycin-C) prior to first dose of NXP900. Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer.
  4. Ongoing toxic manifestations of previous treatments > Grade 2 with the exception of alopecia and neuropathy.
  5. Female subjects who can become pregnant (or are already pregnant or lactating), unless they have a negative serum pregnancy test before enrollment and agree to use at least one highly effective form of contraception .
  6. Male subjects with partners of childbearing potential, unless they agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide).
  7. Major surgery from which the subject has not yet recovered.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Dose Escalation (Part A)

    Escalating doses of NXP900 are planned with a starting dose level of 20 mg once per day.

    Drug: NXP900

  • Experimental
    Dose Expansion (Part B)

    Participants will receive the selected dose of NXP900

    Drug: NXP900

Interventions

  • DrugNXP900

    NXP900 is an orally administered SRC/YES1 kinase inhibitor

06

What researchers measure

Primary outcomes

  1. Number of patients with treatment related adverse events and/or clinical laboratory abnormalities

    Time frame: Up to 30 days post treatment

  2. Part A: Number of patients who experience Dose Limiting Toxicities (DLT) as defined in the protocol

    Time frame: Day 28

  3. Part B: Objective response rate (ORR)

    Best response of complete response (CR) or partial response (PR) per RECIST 1.1 (or mRECIST 1.1 for subjects with pleural mesothelioma).

    Time frame: Up to 24 months

  4. Part B: Duration of Response (DoR)

    Confirmed CR or PR from the first documented response to the date of documented disease progression or death.

    Time frame: Up to 24 months

  5. Part B: Disease Control Rate (DCR)

    The proportion of patients with stable disease (SD), partial response (PR), or complete response (CR).

    Time frame: Up to 24 months

Secondary outcomes

  1. Area under the concentration-time curve (AUC) of NXP900

    Time frame: Up to 24 months

  2. Maximum observed concentration (Cmax) of NXP900

    Time frame: Up to 24 months

  3. Time to peak concentration (Tmax) of NXP900

    Time frame: Up to 24 months

  4. Half-life (T1/2) of NXP900

    Time frame: Up to 24 months

  5. Apparent volume of distribution at steady state (Vss/F) of NXP900

    Time frame: Up to 24 months

  6. Apparent plasma clearance at steady state (Clss/F) of NXP900

    Time frame: Up to 24 months

07

Study locations

15 sites
08

References and documents

Publications

  • Dash S, Hanson S, King B, Nyswaner K, Foss K, Tesi N, Harvey MJB, Navarro-Marchal SA, Woods A, Poradosu E, Unciti-Broceta A, Carragher NO, Brognard J. The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas. J Biol Chem. 2024 Sep;300(9):107615. doi: 10.1016/j.jbc.2024.107615. Epub 2024 Jul 31. PubMed 39089584 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Mar 2027, 41 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 41 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2023
First posted
May 24, 2023
StartActual
Oct 26, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Jul 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05873686
Lead sponsor
Nuvectis Pharma, Inc.
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Oct 26, 2023
Primary completion
Mar 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Udai Banerji, Prof
principal investigator · Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Gerald Falchook, MD
principal investigator · Sarah Cannon Cancer Institute, HealthOne Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SRC/YES1 Kinase Inhibitor NXP900

Start the discussion